bumetanide has been researched along with Cancer of Liver in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, R; Ding, G; Dong, J; Fu, H; Fu, Z; Guo, M; Guo, W; Liu, F; Sun, K; Teng, F; Wang, C; Zhang, L; Zou, Y | 1 |
1 review(s) available for bumetanide and Cancer of Liver
| Article | Year |
|---|---|
Treatment with an SLC12A1 antagonist inhibits tumorigenesis in a subset of hepatocellular carcinomas.
Topics: Animals; Bumetanide; Carcinoma, Hepatocellular; Databases, Genetic; Humans; Liver Neoplasms; Mice; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 1; Xenograft Model Antitumor Assays | 2016 |